Biosimilar Guidances Expected In ‘Near Future,’ But Unnecessary, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Naming and labeling questions will likely be resolved with agency actions on pending biosimilar applications.
You may also be interested in...
Apotex Biosimilar Goes To FDA, But May Enter Crowded Market
Pegfilgrastim product, a collaboration with the Indian firm Intas, may have to compete with multiple filgrastim products, along with its reference biologic, Amgen’s Neulasta.
Sandoz’s Biosimilar Filing Is Culmination Of Paradigm Shift In FDA Drug Review
FDA clinical reviewers moved from traditional “new drug” review mode to determining the evidence needed to demonstrate a follow-on product is highly similar to the reference biologic, Sandoz exec says, describing firm’s interactions with FDA on its filgrastim 351(k) application.
US FDA Finds Pfizer’s COVID Vaccine For Kids 5-11 Worth The Risk Even In Lowest Incidence Model
Overall benefit still favorable when there could be excess hospitalizations due to vaccine-related myocarditis because of ‘the different clinical implications of hospitalization for COVID-19,’ FDA concludes ahead of the advisory committee.